FDA expands ImmunityBio's Anktiva label to papillary-only NMIBC

What happened

The FDA on 14 October 2026 approved an expanded indication for ImmunityBio's Anktiva (nogapendekin alfa inbakicept-pmln) in combination with BCG, adding adults with high-grade papillary-only, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) to a label that until now covered only carcinoma in situ (CIS) with or without papillary tumors ^[1]. ImmunityBio furnished the news in an 8-K the same day, signed by CFO David C. Sachs ^[3]. The company calls it the first FDA approval to include papillary-only disease in this setting ^[2].

The reach is the point. ImmunityBio puts papillary disease at roughly 85% of the NMIBC population ^[2]. The original April 2024 clearance, and the approvals built on it, centred on CIS patients ^[2]; papillary-only patients, the larger group, sat outside the US label until this action.

The efficacy behind the two pieces of the label

The CIS portion rests on Cohort A of QUILT-3.032 (NCT03022825), a single-arm, multicenter trial of 77 patients with BCG-unresponsive, high-risk NMIBC with CIS with or without Ta/T1 papillary disease; the primary endpoint was complete response by cystoscopy, cytology and biopsy ^[1]. In that cohort, 62% of the 77 patients achieved a complete response (95% CI 51 to 73); among responders, 58% held the response for at least 12 months and 40% for at least 24 months ^[2].

The papillary expansion draws on a separate dataset. ImmunityBio's April 2025 release, citing data published in NEJM Evidence, reported disease-free survival of 55% at 12 months, 51% at 18 months and 48% at 24 months in papillary NMIBC patients, with 93% cystectomy avoidance at a median 20.7-month follow-up ^[6]. The company completed the sBLA for the papillary indication in the first quarter of 2025 ^[6].

The label carries a warning that delaying cystectomy can lead to metastatic bladder cancer, which can be lethal ^[2]. For papillary-only patients, who have an organ-sparing alternative in repeat resection and surveillance, that warning frames the clinical bargain: a non-surgical option against the risk of a missed window.

What it changes for the field

The October action closes the gap between the US label and the UAE authorization, the one overseas grant that already spanned both CIS and papillary-only disease ^[7]. Anktiva's CIS reach is already wide: by July 2026 it had reached more than 30 countries, with the UAE the fifth jurisdiction to authorize it after the US, UK, Saudi Arabia and the EU ^[7].

For a BD or R&D lead tracking BCG-unresponsive NMIBC, the signal is market size, not a new mechanism. The efficacy readouts predate this approval; what changed on 14 October is the addressable US population, now formally including the papillary majority the company cites ^[2].

What Prognyx could not verify

The public DailyMed label excerpt still shows the pre-expansion wording that qualifies the indication to CIS, while the company's press release describes a broadened label reading simply "BCG-unresponsive NMIBC" ^[4][2]. Prognyx could not confirm from public sources that DailyMed has republished the updated text, the specific BLA supplement number for this action, or any analyst or revenue estimate tied to the expanded population. The current status of QUILT-3.032 on ClinicalTrials.gov was not in Prognyx's source set.

Now-what

For an operator with a program in BCG-unresponsive NMIBC, two moves follow. Re-size the US opportunity against a label that now spans both CIS and the larger papillary-only group, where the 2024 launch addressed CIS alone ^[2]. And hold off on quoting the exact indication language until DailyMed republishes the updated text, given the gap between the printed label and the company's description ^[4][2].

Verdict: low clinical threat, no new mechanism or randomized comparison in this action, but the US addressable population just widened to include the papillary majority; reassess NMIBC positioning now, before the label text settles in public databases.